AM Study Update: March 15, 2026

Evidence Watch  |  Nature medicine (2025)

Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.

# Study Summary **Finding & Clinical Relevance:** This phase 3 trial evaluated full-spectrum Cannabis sativa extract DKJ127 for chronic low back pain, addressing a major clinical need where current pharmacologic treatments have limited efficacy and safety concerns.

Evidence Watch  |  Acta paediatrica (Oslo, Norway : 1992) (2025)

Cannabinoids for Medical Purposes in Children: A Living Systematic Review.

# Study Summary This living systematic review continuously maps safety and efficacy data on medical cannabinoid use in children, providing clinicians with regularly updated evidence to inform pediatric treatment decisions.

Evidence Watch  |  British journal of sports medicine (2026)

Influences on the mental health and well-being of retired professional athletes from high contact team sports: a mixed methods systematic review.

# Study Summary for Cannabis Clinicians This systematic review examines mental health outcomes and risk factors in retired high-contact team sport athletes, providing evidence on psychiatric symptom prevalence relevant to understanding vulnerable populations seeking cannabis-based treatments.

Evidence Watch  |  Journal of medical Internet research (2024)

Effectiveness of the Minder Mobile Mental Health and Substance Use Intervention for University Students: Randomized Controlled Trial.

# Study Finding Summary The Minder mobile intervention showed effectiveness for mental health and substance use challenges in university students, offering clinicians a scalable digital tool for addressing co-occurring conditions during high-risk developmental periods.

Evidence Watch  |  Journal of anxiety disorders (2024)

Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.

# Study Summary for Cannabis Clinicians The study examines whether evidence-based PTSD treatments remain effective for patients with co-occurring cannabis and substance use disorders, addressing a critical clinical gap for treating this complex patient population.

Evidence Watch  |  BMJ open (2026)

Research on Eating and Adolescent Lifestyle (REAL) 2.0: 15-year follow-up study of eating disorders and weight-related trajectories, mental health and substance use health from early adolescence to early adulthood-a Canadian cohort profile.

# REAL 2.0 Study Summary The abstract provided is incomplete and contains no findings. A one-sentence summary cannot be written without access to the study’s results section.

Evidence Watch  |  Annals of the rheumatic diseases (2026)

Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.

# Study Finding Summary This randomized, double-blind, placebo-controlled trial evaluated cannabidiol’s efficacy versus placebo for fibromyalgia pain, directly addressing the evidence gap for CBD use in this indication.

Evidence Watch  |  International journal of environmental research and public health (2026)

Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.

# Study Summary for Cannabis Clinicians Cannabis flower and edible products show differential effects on anxiety symptoms, with daily use patterns and longitudinal outcomes varying by product type, informing personalized therapeutic recommendations.

Evidence Watch  |  Journal of sleep research (2026)

Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.

# Study Finding Summary This pilot trial examines how single oral doses of THC and CBD affect sleep architecture and daytime function using high-density EEG, addressing clinicians’ need for objective data on cannabinoid efficacy for insomnia treatment.

Evidence Watch  |  Clinical pharmacology and therapeutics (2026)

Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3-Way Crossover Trial.

CBD did not directly reduce cortical excitability in this trial, suggesting its anti-seizure effects may operate through mechanisms other than direct neuronal suppression or pharmacokinetic interactions with concurrent medications.

Evidence Watch  |  Journal of psychiatric research (2025)

Pre-trauma insomnia and posttraumatic alcohol and cannabis use in the AURORA observational cohort study of trauma survivors.

# Study Finding Summary Pre-trauma insomnia predicted increased cannabis use following trauma exposure, suggesting cannabis clinicians should screen trauma patients for prior sleep disturbances as a risk marker for problematic cannabis use patterns.

Evidence Watch  |  JAMA health forum (2026)

Adolescent Cannabis Use and Risk of Psychotic, Bipolar, Depressive, and Anxiety Disorders.

# Study Summary Adolescent cannabis use is associated with increased risk of psychotic, bipolar, depressive, and anxiety disorders, providing clinicians with evidence-based data for risk counseling and early intervention strategies.

Evidence Watch  |  Drug and alcohol dependence (2016)

Anxiety, depression and risk of cannabis use: Examining the internalising pathway to use among Chilean adolescents.

# Study Summary for Cannabis Clinicians Adolescents with internalising symptoms (depression, anxiety) may use cannabis as a coping mechanism, indicating clinicians should screen for and address underlying mental health conditions when treating cannabis use in youth.

Evidence Watch  |  Journal of clinical pharmacology (2025)

Therapeutic Use of Cannabis Derivatives and Their Analogs for Autism Spectrum Disorder: A Systematic Review.

# Study Summary Cannabis derivatives showed promising therapeutic effects for autism spectrum disorder symptoms, with findings relevant to clinical practitioners considering cannabis treatment for this population.

Evidence Watch  |  The Journal of clinical psychiatry (2024)

Maternal Cannabis Use in Pregnancy and Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder in Offspring.

# Study Finding Summary Maternal cannabis use during pregnancy was examined for association with autism spectrum disorder and attention-deficit/hyperactivity disorder in offspring, given cannabis constituents’ placental transfer and fetal brain cannabinoid receptor activity.

Evidence Watch  |  Cannabis and cannabinoid research (2026)

A Randomized, Open-Label Trial to Assess Feasibility and Tolerability of Topical Cannabis Balms for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS).

# Study Summary This feasibility and tolerability trial investigates topical cannabis balms as a potential treatment for aromatase inhibitor-associated musculoskeletal pain in postmenopausal breast cancer patients, addressing a common adverse effect affecting two-thirds of users.

Evidence Watch  |  Psychiatry research. Neuroimaging (2026)

A single dose of cannabidiol modulates the relationship between hippocampal glutamate and learning-related prefrontal activation in individuals at Clinical High Risk of Psychosis.

# Study Finding Summary A single CBD dose altered the relationship between hippocampal glutamate and prefrontal brain activation during learning tasks in individuals at clinical high risk for psychosis, suggesting a potential neurobiological mechanism for CBD’s therapeutic effects.

Evidence Watch  |  Medicine and science in sports and exercise (2026)

Daily Use of a Broad-Spectrum Cannabidiol Supplement Produces Detectable Concentrations of Cannabinoids in Urine Prohibited by the World Anti-Doping Agency: An Effect Amplified by Exercise.

# Study Finding Summary Broad-spectrum CBD supplements contain other cannabinoids that accumulate in urine at detectable levels, especially with exercise, potentially causing positive WADA drug tests despite CBD’s legal status.

Evidence Watch  |  Journal of neurodevelopmental disorders (2025)

Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension study.

# Study Summary ZYN002 (transdermal cannabidiol gel) demonstrated long-term safety and tolerability in pediatric FXS patients, providing clinical evidence for cannabidiol’s potential therapeutic application in this neurodevelopmental disorder.

Evidence Watch  |  Complementary therapies in clinical practice (2025)

Challenges in conducting a feasibility randomized controlled trial of medicinal cannabis for endometriosis pain in Australia.

# Study Finding Summary This feasibility study assessed the practicality and safety of conducting a randomized controlled trial evaluating medicinal cannabis for endometriosis pain management in Australia, addressing a gap in clinical evidence for patient-reported cannabis use.